NASDAQ · PRTG
Healthcare · Biotechnology
$6.81
Down-$0.15 (-2.16%)
Updated Oct 9, 2026, 1:10 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · PRTG
1M range · 0 trading sessions · Daily adjusted prices
PRTG does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning PRTG.
Company
Market Activity
Research & News
PRTG research
Company profile and research snapshot.
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 8, 2024 | HC Wainwright & Co. | Neutral | — |
| Nov 29, 2023 | HC Wainwright & Co. | Buy | — |
| Sep 7, 2023 | Cantor Fitzgerald | Overweight | — |
| Aug 31, 2023 | Cantor Fitzgerald | Overweight | — |
| Aug 2, 2023 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Jun 25, 2025
Portage Biotech, a clinical-stage immuno-oncology company, announced that it has evidenced compliance with all applicable requirements for continued listing on The Nasdaq Capital Market.
GlobeNewswire Inc. · Apr 28, 2025
Portage Biotech reports positive preclinical data for its selective adenosine A2B receptor inhibitor PORT-7 in a murine mesothelioma model, demonstrating superior single-agent activity compared to anti-PD1 antibody and further improvement in combination. The company plans to commence a first-in-human clinical trial with PORT-7.
GlobeNewswire Inc. · Mar 12, 2025
Portage Biotech announced the resumption of patient enrollment in the final cohort of the dose escalation stage for its selective A2A antagonist, PORT-6, within its ADPORT-601 Phase 1b clinical trial. The company is also preparing to evaluate the continuation of the study into its potent and selective A2B antagonist, PORT-7, and combination arms.
GlobeNewswire Inc. · Jan 6, 2025
Portage Biotech is re-launching its wholly-owned adenosine receptor antagonist subsidiary as an independently managed company, Cyncado Therapeutics, with Peter Molloy as the new CEO. The company aims to advance the clinical development of its portfolio of A2a and A2b receptor antagonists, which have the potential to enhance the immune system's ability to fight cancer.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PRTG.
No results
No recent SID articles mention PRTG.
